j*****7
发帖数: 4348 | 1 VICL： 差不多就行了, 至少大部队可以出来了
DSCO： 先出来喘口气儿
PIP： 危险系数非常高，官司输了的话股价下看$1，小心死无葬身之地 |
f**********g
发帖数: 2252 | 2 VICL correction, DSCO keep runnig, PIP correction.
【在 j*****7 的大作中提到】
: VICL： 差不多就行了, 至少大部队可以出来了
: DSCO： 先出来喘口气儿
: PIP： 危险系数非常高，官司输了的话股价下看$1，小心死无葬身之地
|
j*****7
发帖数: 4348 | 3 整数关前停一停。
【在 f**********g 的大作中提到】
: VICL correction, DSCO keep runnig, PIP correction.
|
h*****8
发帖数: 4754 | 4 谢谢。
【在 j*****7 的大作中提到】
: VICL： 差不多就行了, 至少大部队可以出来了
: DSCO： 先出来喘口气儿
: PIP： 危险系数非常高，官司输了的话股价下看$1，小心死无葬身之地
|
f**********g
发帖数: 2252 | 5 PIP target 4.5 5, stop 3.6
【在 f**********g 的大作中提到】
: VICL correction, DSCO keep runnig, PIP correction.
|
i*****1
发帖数: 670 | 6 周末了 今天休息
【在 j*****7 的大作中提到】
: VICL： 差不多就行了, 至少大部队可以出来了
: DSCO： 先出来喘口气儿
: PIP： 危险系数非常高，官司输了的话股价下看$1，小心死无葬身之地
|
h******g
发帖数: 11250 | 7 意思现在不宜马上入？
bpax呢？
【在 j*****7 的大作中提到】
: VICL： 差不多就行了, 至少大部队可以出来了
: DSCO： 先出来喘口气儿
: PIP： 危险系数非常高，官司输了的话股价下看$1，小心死无葬身之地
|
j*****7
发帖数: 4348 | 8 看看DSCO， 昨天量太大了， 今早整数关前悲剧了， 经典走法。
放在watchlist里面， 这个家伙今年一定会有大波动的。 |
f**********g
发帖数: 2252 | 9 Niu, already sold. will watch next week.
【在 j*****7 的大作中提到】
: 看看DSCO， 昨天量太大了， 今早整数关前悲剧了， 经典走法。
: 放在watchlist里面， 这个家伙今年一定会有大波动的。
|
x****7
发帖数: 895 | 10 啥时候提DSCO的？
//前两天刚发现它。很有幸和银杏大牛的看法一致。
【在 j*****7 的大作中提到】
: 看看DSCO， 昨天量太大了， 今早整数关前悲剧了， 经典走法。
: 放在watchlist里面， 这个家伙今年一定会有大波动的。
|
|
|
j*****7
发帖数: 4348 | 11 DSCO似乎可以考虑二进山城了。
几天从１块８拉到３块， 两天又放回２块３， 预期今年三季度要file NDA， 噱头不
缺的。 |
h******g
发帖数: 11250 | 12 刚刚割了DSCO......
【在 j*****7 的大作中提到】
: DSCO似乎可以考虑二进山城了。
: 几天从１块８拉到３块， 两天又放回２块３， 预期今年三季度要file NDA， 噱头不
: 缺的。
|
j*****7
发帖数: 4348 | 13 这么说洗得还比较成功。
【在 h******g 的大作中提到】
: 刚刚割了DSCO......
|
h******g
发帖数: 11250 | 14 ft，周五才入的，亏了不少。。。。。
青蛙今天手感太差，决定停止操作一天
【在 j*****7 的大作中提到】
: 这么说洗得还比较成功。
|
j*****7
发帖数: 4348 | 15 多说两句， 这样的垃圾股没有割的道理。 当然第一呢就不能重仓。 当成不过期的
option来看待就可以了。牛市都进入第三年了， 到现在还没有出头的股票那就是标准
的垃圾， 更不要说这三年来还稳步下降的股票。第二呢， 周四无理由这么大的量，
周五又高开，冲击上次的gap， 所以大家都跑了。不晓得你周五啥时候进的。
【在 h******g 的大作中提到】
: ft，周五才入的，亏了不少。。。。。
: 青蛙今天手感太差，决定停止操作一天
|
v**********m
发帖数: 5516 | 16 靠，你这个回复够直接的。
DSCO也许在file NDA之前还会来几波一样的pattern。毕竟，小散手里的股票太多了，
MM来来回回搞比较有油水。
【在 j*****7 的大作中提到】
: 这么说洗得还比较成功。
|
h******g
发帖数: 11250 | 17 多谢银杏大牛解释
青蛙没经验，还得跟版上众多大牛学习
而且今天早上别的股panic了一下，割掉了。
严重影响心情和判断力
:(
【在 j*****7 的大作中提到】
: 多说两句， 这样的垃圾股没有割的道理。 当然第一呢就不能重仓。 当成不过期的
: option来看待就可以了。牛市都进入第三年了， 到现在还没有出头的股票那就是标准
: 的垃圾， 更不要说这三年来还稳步下降的股票。第二呢， 周四无理由这么大的量，
: 周五又高开，冲击上次的gap， 所以大家都跑了。不晓得你周五啥时候进的。
|
j*****7
发帖数: 4348 | 18 割就割了吧， 没啥的， 谁还能没有个输钱的时候。 稳妥一点的我认为GM－B可以考虑。http://www.mitbbs.com/article_t0/Stock/33534081.html
【在 h******g 的大作中提到】
: 多谢银杏大牛解释
: 青蛙没经验，还得跟版上众多大牛学习
: 而且今天早上别的股panic了一下，割掉了。
: 严重影响心情和判断力
: :(
|
v**********m
发帖数: 5516 | 19 给你个心里安慰，我在DSCO上亏过金灯。
【在 h******g 的大作中提到】
: 多谢银杏大牛解释
: 青蛙没经验，还得跟版上众多大牛学习
: 而且今天早上别的股panic了一下，割掉了。
: 严重影响心情和判断力
: :(
|
h******g
发帖数: 11250 | 20 多谢
青蛙本小，要是亏金灯就直接见外婆了
【在 v**********m 的大作中提到】
: 给你个心里安慰，我在DSCO上亏过金灯。
|
|
|
C**********P
发帖数: 1004 | 21 每次看到银杏的这个头像都觉得很有喜感
【在 j*****7 的大作中提到】
: 多说两句， 这样的垃圾股没有割的道理。 当然第一呢就不能重仓。 当成不过期的
: option来看待就可以了。牛市都进入第三年了， 到现在还没有出头的股票那就是标准
: 的垃圾， 更不要说这三年来还稳步下降的股票。第二呢， 周四无理由这么大的量，
: 周五又高开，冲击上次的gap， 所以大家都跑了。不晓得你周五啥时候进的。
|
j*****7
发帖数: 4348 | 22 你看， 是不是又快回来了？ 不急， 应该还有机会下去的。
【在 h******g 的大作中提到】
: ft，周五才入的，亏了不少。。。。。
: 青蛙今天手感太差，决定停止操作一天
|
f**********g
发帖数: 2252 | 23 DSCO so good today. Sold again around 3?
【在 j*****7 的大作中提到】
: 你看， 是不是又快回来了？ 不急， 应该还有机会下去的。
|
h******g
发帖数: 11250 | 24 青蛙就是不行，稳不住
总在高点买，亏一点就割
【在 j*****7 的大作中提到】
: 你看， 是不是又快回来了？ 不急， 应该还有机会下去的。
|
v**********m
发帖数: 5516 | 25 我觉得也是。
【在 j*****7 的大作中提到】
: 你看， 是不是又快回来了？ 不急， 应该还有机会下去的。
|
D*****a
发帖数: 224 | 26 dsco捞到了低价位，可惜出早了，timing还是看不准 |
f**********g
发帖数: 2252 | 27 U are right again. hehe. Fished some @2.3X today.
【在 j*****7 的大作中提到】
: 你看， 是不是又快回来了？ 不急， 应该还有机会下去的。
|
L**j
发帖数: 948 | |
j*****7
发帖数: 4348 | 29 不喜欢大盘。
【在 L**j 的大作中提到】
: 现在，如何2.38
|
D*****a
发帖数: 224 | 30 总觉得大盘摇摇晃晃，个股很多不是像做顶，就是已经躺在地板上了
【在 j*****7 的大作中提到】
: 不喜欢大盘。
|
|
|
f**********g
发帖数: 2252 | 31 Analysis of Surfaxin Data Presented in First Peer-Reviewed Manuscript
Describing the Consequences of Reintubation in Preterm Neonates
3 hours 8 minutes ago - PMZ via Comtex
GlobeNewswireDiscovery Laboratories, Inc. (Nasdaq:DSCO) announced that the
Journal of Neonatal-Perinatal Medicine, a prominent, peer-reviewed journal
widely distributed to neonatal and pediatric intensive care physicians,
recently published a manuscript reviewing an important data analysis from
the Surfaxin(R) (lucinactant) Phase 3 clinical trial program. The manuscript
is entitled "Reintubation and risk of morbidity and mortality in preterm
infants after surfactant replacement therapy" (Guardia et al.) in the
Journal of Neonatal-Perinatal Medicine (Volume 4, Number 2, 2011). This is
the first peer-reviewed manuscript describing neonatal patient compromise
following reintubation.
The analysis demonstrates that, for preterm infants at risk for respiratory
distress syndrome (RDS) who received prophylactic surfactant therapy and
were extubated, subsequent reintubation is a highly predictive risk factor
for mortality and major complications of prematurity. The analysis also
indicates that infants treated with Surfaxin had a significantly lower
incidence of subsequent reintubation and improved survival without
reintubation, compared with infants who received comparator animal-derived
surfactants Survanta(R) (beractant) and Curosurf(R) (poractant alfa), the
current standard of care.
Premature infants are often born with a lack of natural lung surfactant
resulting in a diagnosis of RDS. The current treatment for moderate to
severe RDS typically requires that the infant be intubated (insertion of a
breathing tube into the infant's airway) to allow for respiratory support
via mechanical ventilation and subsequent surfactant administration. If
surfactant therapy appears to be successful, the endotracheal tube is
removed from the infant's airway (extubated) to allow the infant to breathe
without mechanical support. However, infants who are extubated following
surfactant therapy often relapse and require reintubation. Although
increased mortality and morbidity in adults requiring reintubation is well
described in medical literature, the consequences of reintubation in preterm
infants have not been previously reported.
Data from Discovery Labs' Phase 3 RDS clinical trials were assessed in a
post-hoc analysis to evaluate the consequences of reintubation as well as
the potential effect of surfactant choice on reintubation rates and
subsequent clinical outcomes in preterm infants. The recently published
manuscript highlights the following observations:
-- Infants who were successfully extubated and did not require
reintubation
experienced low mortality rates across all treatment groups, while
infants who were subsequently reintubated had a statistically
significant higher mortality rate, 0.5% vs. 18%, respectively (p <
0.05).
-- Infants who required reintubation had significantly higher rates of
six
major complications of prematurity, including bronchopulmonary
dysplasia
(BPD, a chronic lung condition), necrotizing enterocolitis (a severe
intestinal condition often requiring surgery and loss of bowel),
sepsis,
and intraventricular hemorrhage (bleeding into the brain).
-- Infants treated with Surfaxin demonstrated a significantly lower
reintubation rate compared with those infants treated with
animal-derived surfactants, Curosurf (33% vs. 47% respectively; p <
0.05) and Survanta (35% vs. 43% respectively; p < 0.05).
-- Infants treated with Surfaxin demonstrated a significantly higher
combined outcome of survival without reintubation compared with those
infants treated with animal-derived surfactants, Curosurf (67% vs. 53%
respectively; p < 0.05) and Survanta (65% vs. 57% respectively; p <
0.05).
Dr. Russell Clayton, Vice President of Research and Development of Discovery
Labs, commented, "This article is the first published full description of
the consequences of reintubation in a preterm neonate population, clearly
indicating that, when possible, neonatal medicine practitioners should
choose therapeutic options that will optimize the chances of successful
extubation. This analysis of our Phase 3 clinical trial data suggests that
treatment with Surfaxin may result in lower reintubation rates compared with
treatment with currently available surfactant products. We intend to expand
upon this current analysis, with specific focus on understanding the
potentially favorable impact on NICU health economics by reducing
reintubation frequency in neonates."
Surfaxin is an investigational drug product that has not been approved by
the U.S. Food and Drug Administration (FDA) or any other world health
regulatory authority. Top-line data of this post-hoc analysis was previously
presented at the 2008 American Association for Respiratory Care (AARC)
International Respiratory Congress. The full study results reported above
include information that may be of interest to healthcare practitioners;
however, the clinical relevance of this post-hoc analysis has not been fully
established and further scientific investigation may be warranted.
About Surfaxin
Surfaxin(R) (lucinactant) is Discovery Labs' lead product based on its
proprietary KL4 surfactant technology and represents the first synthetic,
peptide--containing surfactant that, if approved, will provide healthcare
practitioners with an alternative therapy to the currently-approved, animal-
derived surfactants that are standard of care today. The safety and efficacy
of Surfaxin for the prevention of RDS has previously been demonstrated in a
comprehensive Phase 3 clinical program.
Discovery Labs filed a New Drug Application (NDA) for Surfaxin for the
prevention of RDS in premature infants and received a Complete Response
Letter from the FDA in April 2009. Discovery Labs has been conducting a
comprehensive preclinical program intended to satisfy the FDA's requirements
with respect to the final validation of an important quality control
release and stability test for Surfaxin, the fetal rabbit Biological
Activity Test (BAT), and, if successful, anticipates filing a Complete
Response to the 2009 Complete Response Letter in the third quarter of 2011.
After an anticipated six-month FDA review cycle, which is expected to also
include, among other things, pre-approval inspections of Discovery Labs'
manufacturing facility, quality assurance / quality control facilities,
third-party raw material suppliers and testing laboratories, Discovery Labs
anticipates the potential marketing approval of Surfaxin for the prevention
of RDS in premature infants in the United States as early as the first
quarter of 2012.
About the Journal of Neonatal-Perinatal Medicine (JNPM)
The JNPM is a quarterly journal that publishes, peer-reviewed work including
original articles, editorials, reviews, case reports and research content.
The mission of the JNPM is to strengthen research and education of the
neonatal and perinatal community on the optimal physical, mental and social
health and well-being of infants and pregnant mothers through highest
quality publications on neonatal-perinatal medicine and to provide examples
of best practices in order to improve the quality, safety and effectiveness
of mothers-infants' healthcare worldwide. The vision for the journal is to
be 'The Reference Journal' in the field of neonatology. |
